{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:09:50Z","timestamp":1785391790395,"version":"3.55.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.rpth.2024.102670","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T12:11:34Z","timestamp":1735647094000},"page":"102670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recombinant factor VIIa: new insights into the mechanism of action through product innovation"],"prefix":"10.1016","volume":"9","author":[{"given":"Miguel A.","family":"Escobar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureane","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Percy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Reding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102670_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1160\/TH14-05-0407","article-title":"Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study","volume":"114","author":"Tagliaferri","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"Mannucci","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102670_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102670_bib4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib5","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib6","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102670_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102670_bib8","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ejh.13108","article-title":"The socioeconomic burden of patients affected by hemophilia with inhibitors","volume":"101","author":"D'Angiolella","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2024.102670_bib10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"Impact of inhibitors on hemophilia A mortality in the United States","volume":"90","author":"Walsh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2024.102670_bib11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2516.2007.01518.x","article-title":"European study on orthopaedic status of haemophilia patients with inhibitors","volume":"13","author":"Morfini","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102415","article-title":"Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review","volume":"8","author":"Young","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib13","series-title":"HEMA Biologics LLC\/LFB","year":"2022"},{"key":"10.1016\/j.rpth.2024.102670_bib14","unstructured":"FEIBA [package insert]. Takeda Pharmaceuticals, Lexingon, MA,\u00a02020."},{"key":"10.1016\/j.rpth.2024.102670_bib15","unstructured":"NOVOSEVEN [package insert]. Novo Nordisk, Bagsvaerd, Denmark,\u00a02014."},{"key":"10.1016\/j.rpth.2024.102670_bib16","first-page":"1","article-title":"Bioengineering of rFVIIa biopharmaceutical and structure characterization for biosimilarity assessment","volume":"5","author":"Montacir","year":"2018","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.rpth.2024.102670_bib17","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12185-020-02837-6","article-title":"Plasma-derived factors VIIa and X mixtures (Byclot) significantly improve impairment of coagulant potential ex\u00a0vivo in plasmas from acquired hemophilia A patients","volume":"111","author":"Ochi","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2024.102670_bib18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A\u00a0randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib19","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/jth.12634","article-title":"Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa","volume":"12","author":"Lentz","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2516.2009.02012.x","article-title":"FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre","volume":"15","author":"Smejkal","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2516.2006.01379.x","article-title":"The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor","volume":"12","author":"N\u00e9grier","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1538-7836.2006.01772.x","article-title":"A\u00a0prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors","volume":"4","author":"Santagostino","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2516.2010.02403.x","article-title":"Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia","volume":"17","author":"Almagro","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0268-960X(08)70001-8","article-title":"From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors","volume":"22","author":"Gomperts","year":"2008","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2024.102670_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2516.2004.00912.x","article-title":"Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors","volume":"10","author":"Schneiderman","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib26","first-page":"335","article-title":"Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)","volume":"10","author":"Rajpurkar","year":"2019","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.rpth.2024.102670_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2516.2002.00532.x","article-title":"Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events","volume":"8","author":"Ehrlich","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib28","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/jth.14296","article-title":"The future of bypassing agents for hemophilia with inhibitors in the era of novel agents","volume":"16","author":"Shapiro","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102670_bib30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/hae.12994","article-title":"TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity","volume":"22","author":"Mahlangu","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib31","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/jth.12237","article-title":"40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors","volume":"11","author":"Ljung","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib32","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/psp4.12872","article-title":"Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: a novel hemostatic drug","volume":"11","author":"Faraj","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.rpth.2024.102670_bib33","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/hae.13301","article-title":"PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding","volume":"23","author":"Wang","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib34","unstructured":"Biosimilars. U.S. Food & Drug Adminstration,\u00a02023."},{"key":"10.1016\/j.rpth.2024.102670_bib35","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/hae.14419","article-title":"The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors","volume":"27","author":"Escobar","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0021-9258(19)70127-6","article-title":"Isolation and characterization of human factor VII. Activation of factor VII by factor Xa","volume":"256","author":"Bajaj","year":"1981","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.rpth.2024.102670_bib37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3324\/haematol.2020.248542","article-title":"Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis","volume":"106","author":"Bernardi","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102670_bib38","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1111\/j.1538-7836.2005.01478.x","article-title":"Post-translational modifications in proteins involved in blood coagulation","volume":"3","author":"Hansson","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib39","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1021\/bi00420a030","article-title":"Amino acid sequence and posttranslational modification of human factor VIIa","volume":"27","author":"Thim","year":"1988","journal-title":"Biochemistry"},{"key":"10.1016\/j.rpth.2024.102670_bib40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2011.04223.x","article-title":"Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity","volume":"9","author":"Hoffman","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib41","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.biochi.2009.05.015","article-title":"The influence of different glycosylation patterns on factor VII biological activity","volume":"91","author":"Sutkeviciute","year":"2009","journal-title":"Biochimie"},{"key":"10.1016\/j.rpth.2024.102670_bib42","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1160\/TH07-05-0332","article-title":"All post-translational modifications except propeptide cleavage are required for optimal secretion of coagulation factor VII","volume":"98","author":"Bolt","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib43","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3389\/fchem.2020.00622","article-title":"Protein glycoengineering: an approach for improving protein properties","volume":"8","author":"Ma","year":"2020","journal-title":"Front Chem"},{"key":"10.1016\/j.rpth.2024.102670_bib44","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood-2012-10-415000","article-title":"Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities","volume":"121","author":"Preston","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib45","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3390\/ijms17121969","article-title":"Effects of glycosylation on the enzymatic activity and mechanisms of proteases","volume":"17","author":"Goettig","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rpth.2024.102670_bib46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12896-015-0205-1","article-title":"Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells","volume":"15","author":"Bohm","year":"2015","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.rpth.2024.102670_bib47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-2001-16890","article-title":"Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development","volume":"27","author":"Jurlander","year":"2001","journal-title":"Sem Thromb Haem"},{"key":"10.1016\/j.rpth.2024.102670_bib48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-1759(99)00151-9","article-title":"Transgenic milk as a method for the production of recombinant antibodies","volume":"231","author":"Pollock","year":"1999","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.rpth.2024.102670_bib49","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/glycob\/cwt085","article-title":"N-\/O-glycosylation analysis of human FVIIa produced in the milk of transgenic rabbits","volume":"23","author":"Chevreux","year":"2013","journal-title":"Glycobiology"},{"key":"10.1016\/j.rpth.2024.102670_bib50","doi-asserted-by":"crossref","first-page":"11051","DOI":"10.1016\/S0021-9258(18)99126-X","article-title":"Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine","volume":"266","author":"Bjoern","year":"1991","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.rpth.2024.102670_bib51","doi-asserted-by":"crossref","first-page":"20320","DOI":"10.1016\/S0021-9258(19)47065-8","article-title":"Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl2-Glc) O-glycosidically linked to a serine residue in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z","volume":"264","author":"Nishimura","year":"1989","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.rpth.2024.102670_bib52","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1021\/acs.biochem.2c00266","article-title":"Molecular view into preferential binding of the factor VII Gla domain to phosphatidic acid","volume":"61","author":"Muller","year":"2022","journal-title":"Biochemistry"},{"key":"10.1016\/j.rpth.2024.102670_bib53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0014-5793(96)00400-0","article-title":"Site-directed mutagenesis but not gamma-carboxylation of Glu-35 in factor VIIa affects the association with tissue factor","volume":"385","author":"Persson","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1016\/j.rpth.2024.102670_bib54","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1111\/hae.13253","article-title":"Biochemical characterization of LR769, a new recombinant factor VIIa bypassing agent produced in the milk of transgenic rabbits","volume":"23","author":"Chevreux","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib55","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A\u00a0cell based model of hemostasis","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib56","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/hae.13357","article-title":"Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors","volume":"23","author":"Ducore","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/hae.12570","article-title":"Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay","volume":"21","author":"Tran","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib58","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2141.2005.05820.x","article-title":"High dose factor VIIa improves clot structure and stability in a model of haemophilia B","volume":"131","author":"Wolberg","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102670_bib59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood.V99.1.175","article-title":"Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A","volume":"99","author":"Lisman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib60","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1538-7836.2005.01227.x","article-title":"Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count","volume":"3","author":"Lisman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib61","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/2040620717737701","article-title":"Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date","volume":"8","author":"Giansily-Blaizot","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2024.102670_bib62","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.blre.2014.12.004","article-title":"The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa","volume":"29","author":"Lisman","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2024.102670_bib63","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood.2020008417","article-title":"Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect","volume":"137","author":"Das","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib64","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1021\/bi00362a005","article-title":"Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine","volume":"25","author":"Bach","year":"1986","journal-title":"Biochemistry"},{"key":"10.1016\/j.rpth.2024.102670_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2006-933336","article-title":"Sources of tissue factor","volume":"32","author":"Osterud","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102670_bib66","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/bi035738i","article-title":"Similar molecular interactions of factor VII and factor VIIa with the tissue factor region that allosterically regulates enzyme activity","volume":"43","author":"Kelley","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.rpth.2024.102670_bib67","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0049-3848(85)90270-1","article-title":"Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor","volume":"40","author":"Nemerson","year":"1985","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102670_bib68","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1538-7836.2007.02576.x","article-title":"Tissue factor around dermal vessels has bound factor VII in the absence of injury","volume":"5","author":"Hoffman","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib69","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1021\/bi00492a016","article-title":"Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor","volume":"29","author":"Komiyama","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.rpth.2024.102670_bib70","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1021\/bi00866a029","article-title":"The reaction between bovine brain tissue factor and factors VII and X","volume":"5","author":"Nemerson","year":"1966","journal-title":"Biochemistry"},{"key":"10.1016\/j.rpth.2024.102670_bib71","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.V95.4.1330.004k28_1330_1335","article-title":"Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa","volume":"95","author":"van\u2019t Veer","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib72","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.V99.3.923","article-title":"Mechanism of FVIIa-dependent coagulation in hemophilia blood","volume":"99","author":"Butenas","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib73","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2011-11-393371","article-title":"Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids","volume":"120","author":"Shibeko","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib74","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1172\/JCI110644","article-title":"Binding of human factor VII and VIIa to monocytes","volume":"70","author":"Broze","year":"1982","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.rpth.2024.102670_bib75","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1016\/S0021-9258(19)83823-1","article-title":"The dual role of factor VII in blood coagulation. Initiation and inhibition of a proteolytic system by a zymogen","volume":"257","author":"Zur","year":"1982","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.rpth.2024.102670_bib76","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1182\/blood-2014-05-576892","article-title":"In\u00a0vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia","volume":"124","author":"Augustsson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0037-1963(01)90140-4","article-title":"The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis","volume":"38","author":"Hoffman","year":"2001","journal-title":"Semin Hematol"},{"key":"10.1016\/j.rpth.2024.102670_bib78","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/hae.13110","article-title":"Kinetic analysis and binding studies of a new recombinant human factor VIIa for treatment of haemophilia","volume":"23","author":"Grandoni","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib79","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/jth.13141","article-title":"Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity","volume":"13","author":"Mahlangu","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib80","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1042\/bj2650327","article-title":"The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII","volume":"265","author":"Bom","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/j.rpth.2024.102670_bib81","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V75.5.1069.1069","article-title":"Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa","volume":"75","author":"Rao","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib82","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","article-title":"Platelet activity of high-dose factor VIIa is independent of tissue factor","volume":"99","author":"Monroe","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102670_bib83","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/j.1538-7836.2004.01015.x","article-title":"Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets","volume":"2","author":"Gabriel","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"issue":"Supplement 1","key":"10.1016\/j.rpth.2024.102670_bib84","first-page":"S15","article-title":"A\u00a0possible mechanism of action of activated factor VII independent of tissue factor","volume":"9","author":"Monroe","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2024.102670_bib85","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/jth.14165","article-title":"Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity","volume":"16","author":"Fager","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib86","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2008-02-139113","article-title":"The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface","volume":"112","author":"Weeterings","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib87","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1538-7836.2009.03532.x","article-title":"Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice","volume":"7","author":"Holmberg","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib88","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood-2013-08-522987","article-title":"FVIIa as used pharmacologically is not TF dependent in hemophilia B mice","volume":"123","author":"Feng","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib89","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jth.13244","article-title":"Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice","volume":"14","author":"Keshava","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib90","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/jth.14881","article-title":"Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms","volume":"18","author":"Keshava","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib91","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.ATV.0000031340.68494.34","article-title":"Platelets and thrombin generation","volume":"22","author":"Monroe","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102670_bib92","doi-asserted-by":"crossref","first-page":"13583","DOI":"10.1073\/pnas.241339498","article-title":"Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity","volume":"98","author":"Persson","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rpth.2024.102670_bib93","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-05-578328","article-title":"Endothelial cell protein C receptor: a multiliganded and multifunctional receptor","volume":"124","author":"Rao","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib94","doi-asserted-by":"crossref","first-page":"11849","DOI":"10.1074\/jbc.M609283200","article-title":"Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium","volume":"282","author":"Ghosh","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.rpth.2024.102670_bib95","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1538-7836.2007.02648.x","article-title":"Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity","volume":"5","author":"Lopez-Sagaseta","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib96","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1160\/TH11-09-0672","article-title":"Factor VIIa binding to endothelial cell protein C receptor: differences between mouse and human systems","volume":"107","author":"Sen","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib97","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood-2014-04-567297","article-title":"The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in\u00a0vivo","volume":"124","author":"Pavani","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib98","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/bloodadvances.2016004143","article-title":"Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action","volume":"1","author":"Keshava","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102670_bib99","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2014-09-600254","article-title":"Blockade of endothelial cell protein C receptor augments factor VIIa hemostatic effect in hemophilia treatment","volume":"124","author":"Sundaram","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","article-title":"Targeting activated protein C to treat hemophilia","volume":"24","author":"Polderdijk","year":"2017","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.rpth.2024.102670_bib101","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC-specific serpin for the treatment of hemophilia","volume":"129","author":"Polderdijk","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.rpth.2024.102670_bib102","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2023-179969","article-title":"Serpin-PC in persons with severe hemophilia (PwH): updated results from a multicenter multi-part, first-in-human study","volume":"142","author":"Baglin","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib103","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1182\/blood-2009-03-208900","article-title":"Endothelial cell protein C receptor cellular localization and trafficking: potential functional implications","volume":"114","author":"Nayak","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib104","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1538-7836.2009.03696.x","article-title":"Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)","volume":"8","author":"Gopalakrishnan","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib105","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1055\/s-0039-1688907","article-title":"Increased accumulation and retention of rhFVIIa (eptacog beta) in knee joints of hemophilia A mice compared to wild-type mice","volume":"119","author":"Magisetty","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib106","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1111\/j.1538-7836.2012.04917.x","article-title":"Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa","volume":"10","author":"Clark","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib107","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/j.1538-7836.2010.04010.x","article-title":"rFVIIa transported from the blood stream into tissues is functionally active","volume":"8","author":"Gopalakrishnan","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib108","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.201211138","article-title":"Extracellular vesicles: exosomes, microvesicles, and friends","volume":"200","author":"Raposo","year":"2013","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.rpth.2024.102670_bib109","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1182\/blood-2010-09-310706","article-title":"Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection","volume":"117","author":"Sen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib110","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/ATVBAHA.120.314244","article-title":"FVIIa (Factor VIIa) induces biased cytoprotective signaling in mice through the cleavage of PAR (Protease-Activated Receptor)-1 at canonical Arg41 (Arginine41) site","volume":"40","author":"Kondreddy","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102670_bib111","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2021012358","article-title":"Factor VIIa suppresses inflammation and barrier disruption through the release of EEVs and transfer of microRNA 10a","volume":"139","author":"Das","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102670_bib112","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/jth.15768","article-title":"Factor VIIa treatment increases circulating extracellular vesicles in hemophilia patients: implications for the therapeutic hemostatic effect of FVIIa","volume":"20","author":"Das","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib113","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/jth.12532","article-title":"Factor VIIa binding to endothelial cell protein C receptor protects vascular barrier integrity in\u00a0vivo","volume":"12","author":"Sundaram","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib114","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1055\/s-0038-1641755","article-title":"Vascular permeability and remodelling coincide with inflammatory and reparative processes after joint bleeding in factor VIII-deficient mice","volume":"118","author":"Cooke","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib115","doi-asserted-by":"crossref","first-page":"26569","DOI":"10.1074\/jbc.271.43.26569","article-title":"Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity","volume":"271","author":"Higashi","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.rpth.2024.102670_bib116","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/ATVBAHA.115.305996","article-title":"Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein","volume":"36","author":"Mast","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102670_bib117","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1160\/TH08-10-0699","article-title":"Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors","volume":"101","author":"Petersen","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib118","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.thromres.2010.12.016","article-title":"In\u00a0vivo clearance and metabolism of recombinant activated factor VII (rFVIIa) and its complexes with plasma protease inhibitors in the liver","volume":"127","author":"Seested","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102670_bib119","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1159\/000321161","article-title":"Recombinant activated factor VII is reabsorbed in renal proximal tubules and is a ligand to megalin and cubilin","volume":"117","author":"Seested","year":"2011","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.rpth.2024.102670_bib120","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1160\/TH10-06-0356","article-title":"The unsialylated subpopulation of recombinant activated factor VII binds to the asialo-glycoprotein receptor (ASGPR) on primary rat hepatocytes","volume":"104","author":"Seested","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib121","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/jth.13502","article-title":"LDL receptor-related protein 1 contributes to the clearance of the activated factor VII-antithrombin complex","volume":"14","author":"Fazavana","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib122","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1538-7836.2010.04152.x","article-title":"Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients","volume":"9","author":"Agerso","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102670_bib123","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/clpt.1994.80","article-title":"Pharmacokinetics and pharmacodynamics of recombinant factor VIIa","volume":"55","author":"Lindley","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rpth.2024.102670_bib124","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/hae.15094","article-title":"Real-world effectiveness of eptacog beta in patients with haemophilia and inhibitors: a multi-institutional case series","volume":"30","author":"Youkhana","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102670_bib125","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1055\/s-0040-1722187","article-title":"Uncovering membrane-bound models of coagulation factors by combined experimental and computational approaches","volume":"121","author":"Ohkubo","year":"2021","journal-title":"Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924003650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924003650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:15:31Z","timestamp":1762629331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924003650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2475037924003650"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102670","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant factor VIIa: new insights into the mechanism of action through product innovation","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102670"}}